

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0005US1	Application No. 10/567,266
	Applicant Eichner et al.		
	Filing Date 05-29-2008		Group Art Unit 1623

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2002/0065410	05/30/2002	Antrim			
	2	2003/0087877	05/08/2003	Calias et al.			
	3	2003/0191291	10/09/2003	Kochendoerfer et al.			
	4	2006/0194940	08/31/2006	Kozlowski			
	5	2007/134197	06/14/2007	Eichner et al.			
	6	2008/0274948	11/06/2008	Eichner et al.			
	7	2009/0091549	04/09/2009	Matsumoto et al.			
	8	3, 226, 395	12/28/1965	Schimmelschmidt et al.			
	9	4, 454, 161	06/12/1984	Okada et al.			
	10	4,939, 239	07/03/1990	Matsushashi et al.			
	11	5, 073, 628	12/17/1991	Matsushashi et al.			
	12	5, 110, 909	05/05/1992	Dellacherie et al.			
	13	5, 420, 105	05/30/1995	Gustavson et al.			
	14	5, 736, 533	04/07/1998	Simon et al.			
	15	5, 770, 645	06/23/1998	Stamler et al.			
	16	5, 840, 900	11/24/1998	Greenwald et al.			
	17	5, 977, 163	11/02/1999	Li et al.			
	18	5, 981, 507	11/09/1999	Josephson et al.			
	19	5, 990, 237	11/23/1999	Bentley et al.			
	20	6, 172, 208	01/09/2001	Cook			
	21	6, 395, 266	05/28/2002	Martinez et al.			
	22	6, 417, 347	07/09/2002	Herrmann et al.			
	23	6,451, 337	09/17/2002	Smith et al.			
	24	6,544, 503	04/08/2003	Vanderhoff et al.			
	25	6, 596, 861	07/22/2003	Moreau			
	26	6, 624, 142	09/23/2003	Greenwald et al.			
	27	6, 916, 962	07/12/2005	Rosen et al.			

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 14503-0005US1	Application No. 10/567,266
	Applicant Eichner et al.			
	Filing Date 05-29-2008		Group Art Unit 1623	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	28	6, 596, 135	07/22/2003	Mitsui			
	29	7, 157, 546	01/02/2007	Kozlowski			
	30	7, 279, 176	10/09/2007	West et al.			
	31	7, 538, 092	05/26/2009	Orlando et al.			
	32	7, 541, 328	06/02/2009	Hemberger et al.			
	33	7, 815, 893	10/19/2010	Zander et al.			
	34	7, 816, 516	10/19/2010	Sommermeier et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	35	5238393	06/23/1994	AU				
	36	2,110,543	06/10/1994	CA				
	37	279 486	06/06/1990	DD				
	38	100 41 541	03/14/2002	DE				
	39	101 12 825	10/02/2002	DE				
	40	101 26 158	12/12/2002	DE				
	41	101 29 369	03/06/2003	DE				
	42	101 35 694	02/06/2003	DE				
	43	101 55 098	05/22/2003	DE				
	44	102 09 821	09/25/2003	DE				
	45	102 17 994	11/06/2003	DE				
	46	102 54 745	06/03/2004	DE				
	47	102 56 558	12/04/2002	DE				
	48	196 28 705	01/15/1998	DE				
	49	198 08 079	08/26/1999	DE				
	50	22 33 977	02/01/1973	DE				
	51	26 07 706	01/04/1977	DE				

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0005US1	Application No. 10/567,266
	Applicant Eichner et al.		
	Filing Date 05-29-2008		Group Art Unit 1623

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	52	26 16 086	11/03/1977	DE				
	53	30 29 307	03/04/1982	DE				
	54	35 01 616	07/17/1986	DE				
	55	38 36 600	05/03/1990	DE				
	56	41 30 807	03/18/1993	DE				
	57	0 338 916	10/25/1989	EP				
	58	0 661 294	07/05/1995	EP				
	59	0 806 140	11/12/1997	EP				
	60	1 496 076	01/12/2005	EP				
	61	1, 591, 467	11/02/2005	EP				
	62	1, 660, 134	12/29/2010	EP				
	63	2 070 950	06/17/2009	EP				
	64	1, 665 06	02/17/2010	IL				
	65	10287554	10/27/1998	JP				
	66	2001-294601	10/23/2001	JP				
	67	00/18893	04/06/2000	WO				
	68	00/66633	11/09/2000	WO				
	69	01/78682	10/25/2001	WO				
	70	01/83522	11/08/2001	WO				
	71	01/93862	12/13/2001	WO				
	72	97/30148	08/21/1997	WO				
	73	02/28841	04/11/2002	WO				
	74	03/049699	06/19/2003	WO				
	75	04/022630	03/18/2004	WO				
	76	05/072778	08/11/2005	WO				
	77	05/083103	09/09/2005	WO				
	78	05/092369	10/06/2005	WO				

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0005US1	Application No. 10/567,266
	Applicant Eichner et al.		
	Filing Date 05-29-2008		Group Art Unit 1623

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	79	05/112954	12/01/2005	WO				
	80	07/053292	05/10/2007	WO				
	81	10/042638	04/15/2010	WO				
	82	92/11037	07/09/1992	WO				
	83	93/24476	12/09/1993	WO				
	84	97/42225	11/13/1997	WO				
	85	98/05689	02/12/1998	WO				
	86	98/07713	02/26/1998	WO				
	87	98/14212	04/09/1998	WO				
	88	98/14215	04/09/1998	WO				
	89	99/17783	04/15/1999	WO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	90	ALAGON et al., "Activation of Polysaccharides with 2-lminothiolane and its uses," <u>Biochem.</u> 19:4341-4345 (1980)
	91	ANNO et al., "Basic of Sugar chemistry," pp. 1-5 (1995) (w/ translation)
	92	BALAZY et al., "S-Nitroglutathione, a Product of the Reaction between Peroxynitrite and Glutathione that Generates Nitric Oxide," <u>J. Biol. Chem.</u> 273(48):32009-32015 (1998)
	93	BAYER et al., "The Avidin-Biotin Complex in Affinity Cytochemistry," <u>Meth Enzymol.</u> 62:308-315 (1979)
	94	BERNARDES et al. "The Direct Formation of GlycosylThiols from Reducing Sugars Allows One-Pot Protein Glycoconjugation," <u>Angew Chem.</u> 118:4111-4115 (2006)
	95	BESHEER et al., "Enzymatically Catalyzed HES Conjugation Using Microbial Transglutaminase:Proof of Feasibility," <u>J. Pharm. Sci.</u> 98(11):4420-4428 (2009)
	96	BOYER et al., "Reaction in Biphasic Water/Organic Solvent System in the Presence of Surfactant:Inverse Phase Transfer Catalysis versus Interfacial Catalysis," <u>Tetrahedron</u> 56:303-307 (2000)
	97	CAREY AND SUNDBERG. "Organische Chemie." VCH Verlagsgesellschaft mbH. Weinheim (DE) (1995)
	98	CAVALLARO et al., "Folate-mediated targeting of polymeric conjugates of gemcitabine," <u>Int. J. Pharmaceut.</u> 307:258-269 (2006)
	99	ETRYCH et al., "New HPMA Copolymers containing doxorubicin bound via pH-sensitive linkage:synthesis and preliminary in vitro and in vivo biological properties," <u>J. Controlled Release</u> 73:89-102 (2001)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0005US1	Application No. 10/567,266
		Applicant Eichner et al.	
		Filing Date 05-29-2008	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	100	GERWECH et al., "Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics," <u>Mol. Cancer Ther.</u> 5(5):1275-2179 (2006)
	101	GLADERBLOM et al., "Cremophor El:the drawbacks and advantages of vehicle selection for drug formulation," <u>Eur. J. Cancer</u> 37:1590-1598 (2001)
	102	GREENWALD et al., "Drug Delivery Systems:Water Soluble Taxol 2'-Poly (ethylene glycol) Ester Prodrugs- Design and in Vivo Effectiveness," <u>J. Med. Chem.</u> 39:424-431 (1996)
	103	GRIECO et al., "Favored Reduction of α -Chlorosilanes vs. α -Chloroalkanes with Tri-n-butyltin Hydride," <u>J. Org. Chem.</u> 43(6):1285 (1978)
	104	HAMILTON et al., Characterization of Human Ovarian Carcinoma Cell Line (NIH:OVCAR-3) with Androgen and Estrogen Receptors," <u>Cancer Res.</u> 43:5379-5389 (1983)
	105	HARADA et al. "Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor-and tumor-bearing rats," <u>J. Controlled Release</u> 71:71-86 (2001)
	106	HARADA et al., Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate," <u>J. Controlled Release</u> 69:399-412 (2000)
	107	HEINDEL et al, "Hydrazide Pharmaceuticals as Conjugates to Polyaldehyde Dextran" <u>Bioconjugate Chem.</u> 1:77-82 (1990)
	108	HEITZMANN AND RICHARDS, "Use of the Avidin-Biotin Complex for Specific Staining of Biological Membranes in Electron Microscopy," <u>Proc. Natl. Acad. Sci. USA</u> 71(9):3537-3561 (1974)
	109	JUNGHEINRICH et al., "Pharmacokinetics of Hydroxyethyl Starch," <u>Clin. Pharmacokinet.</u> 44 (7):681-699 (2005)
	110	KATSUMI et al., "Development of Polyethylene Glycol-Conjugated Poly-S Nitrosated Serum Albumin, a Novel S-Nitrosothiol for Prolonged Delivery of Nitric Oxide in the Blood Circulation in Vivo," <u>J. Pharmacol. Exp. Ther.</u> 314(3):1117-1124 (2005)
	111	KINSTLER et al., "Characterization and Stability of N-terminally PEGylated rhG-CSF," <u>Pharmaceut. Res.</u> 13 (7):996-1002 (1996)
	112	KLEINE-TEBBE et al., "Allergen Immunotherapy – A Position Paper of the German Society for Allergology and Clinical Immunology," <u>Pneumologie</u> 55:438-444 (2001) (w/English summary)
	113	KULICKE et al., "Measurements of the Refractive Index Increment on Hydroxyethyl Starch as a Basis for Absolute Molecular Weight Determinations," <u>Starch</u> 43(10):392-396 (1991)
	114	LAINE et al., "Polyethylene Glycol Nephrotoxicity Secondary to Prolonged High-Dose Intravenous Lorazepam," <u>Ann. Pharmacother.</u> 29:1110-1114 (1995)
	115	LEE et al., "Functional Polymers for Layer-by-Layer Construction of Multilayer via Chemoselective Immobilization," <u>Macromolecules</u> 37:1849-1856 (2004)
	116	LEE, Ed., <u>Peptide and Protein Drug Delivery</u> , Marcel Dekker, 1991, Page 65
	117	LEWIS et al., "The phase transfer catalysed synthesis of isoflavone-O-glucosides," <u>J. Chem. Soc. Perkins Trans.</u> 1:2481-2484 (1998)
	118	LEWIS AND WÄHÄLÄ, "Regiospecific 4'-O- β -glucosidation of isoflavones," <u>Tetrahedron Lett.</u> 39(51):9559-9562 (1998)
	119	LIEBER et al., "A Continuous Tumor-Cell Line From a Human Lung Carcinoma with Properties of Type II Alveolar Epithelial Cells," <u>Int. J. Cancer</u> 17:62-70 (1976)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0005US1	Application No. 10/567,266
		Applicant Eichner et al.	
		Filing Date 05-29-2008	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	120	LIPKE et al., "Localized Delivery of Nitric Oxide from Hydrogels Inhibits Neointima Formation in Rat Cartoid Ballon Injury Model," <u>Acta Biomaterialia</u> 1:597-606 (2005)
	121	LUND et al., Assessment of methods for covalent binding of nucleic acids to magnetic beads, Dynabeads, and the characteristics of the bound nucleic acids in hybridization reactions," <u>Nucl. Acids Res.</u> 16(22):10861-10880 (1988)
	122	MEGSON et al., "Inhibition of Human Platelet Aggregation by a Novel S-Nitrosothiol is Abolished by Hemoglobin and Red Blood Cell in vitro:Implications for Anti-Thrombotic Therapy," <u>Brit. J. Pharmacol.</u> 131:1391-1398 (2000)
	123	NATHAN et al., "Strategies for Covalent Attachment of Doxorubicin to Ply (PEG-Lys), a New Water Soluble Poly (etherurethane)," <u>J. Bioactive Compatible Polymers</u> , 9:239-251 (1994)
	124	Organikum, Organisch-chemisches Grundpraktikum, 1984, <u>VEB Deutscher Verlag der Wissenschaften</u> , p. 472 (with verified English translation)
	125	PASUT et al., "Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid," <u>J. Controlled Release</u> 127(3):239-248 (2008)
	126	PERI et al, "Chemo- and Stereoselective Glycosylation of Hydroxylamino Derivatives:A Versatile Approach to Glycoconjugates," <u>Tetrahedron</u> 54:12269-12278 (1998)
	127	PETERSON, the physiological inhibitors of blood coagulation and fibrinolysis, elsevier/ north-holland biomedical press 1979, <u>TOC Editor: Collen</u>
	128	REYNOLDS et al., "S-nitrosohemoglobin deficiency:A mechanism for loss of physiological activity in banked blood," <u>Proc. Natl. Acad. Sci. USA</u> 104(43):17058-17062 (2007)
	129	SALO et al., "Aminoxy Functionalized Oligonucleotides:Preparation, On-Support Derivitization and Postsynthetic Attachment to Polymer Support," <u>Bioconjugate Chem.</u> 10:815-823 (1999)
	130	SCHNEERSON et al., "Preparation, characterization and immunogenicity of haemophilus influenzae type b polysaccharide-protein conjugates," <u>J. Exp. Med.</u> 152:361-376 (1980)
	131	SEYMOUR et al., "A phase 1 study of BAY 38-3441 given as a short infusion daily for five days every 3 weeks. A National Cancer Institute of Canada Clinical Trials Group Study," <u>Eur. J. Cancer</u> 37(1):73 (2001) p. 573
	132	SKOPP et al., "Fingerprinting of proteins cleaved in solution by cyanogen bromide," <u>Appl. Theoret. Electrophoresis</u> 1:61-64 (1989)
	133	SKWARCZYNSKI et al., "Paclitaxel Prodrugs Toward Smarter Delivery of Anticancer Agents," <u>J. Med. Chem.</u> 49(25):7253-7269 (2006)
	134	STIEN et al., "Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo," <u>Int. J. Cancer</u> 72:885-891 (1997)
	135	SVENSON AND LINDBERG, "Coupling of Acid Labile Salmonella Specific Oligosaccharides to Macromolecular Carriers," <u>J. Immunolog. Meth.</u> 25:323-335 (1979)
	136	SVENSON, "Immunochemistry of Salmonella O-antigens:Preparation of an Octasaccharide-Bovine Serum Albumin Immunogen Representative of Salmonella Serogroup B O-Antigen and Characterization of the Antibody Response," <u>J. Immunol.</u> 120(5):1750-1757 (1978)
	137	Thermo Scientific Pierce, <u>Crosslinking Technical Handbook</u> , 48 pgs. (2009)
	138	TOMASIK et al., "Chemical Modification of Starch," <u>Adv. Carbohydrate Chem. Biochem.</u> , 59:179-403 (2004)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0005US1	Application No. 10/567,266
	Applicant Eichner et al.		
	Filing Date 05-29-2008		Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	139	VASEY et al., :Phase I Clinical and Pharmacokinetic Study of PKI [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]:First Member of a New Class of Chemotherapeutic Agents-Drug-Polymer Conjugates," <u>Clin. Cancer Res.</u> 5:83-94, (1999)
	140	WALTZINGER et al., "Pharmacokinetics and Tolerability of a New Hydroxyethyl Starch (HES) Specification [HE (130/0.4)] after Single-Dose Infusion of 6% or 10% Solutions in Healthy Volunteers," <u>Pharmacokinetics</u> 16(2):151-160 (1998)
	141	WANG et al., "Delivery of Antisense Oligonucleotides Using HPMA Polymer:Synthesis of a Thiol Polymer and its Conjugation to Water-soluble Molecules," <u>Bioconj. Chem.</u> 9:749-757 (1998)
	142	ZHANG et al. "Thiazolidine formation as a general and site-specific conjugation method," <u>Anal. Biochem.</u> 233:87-93 (1996)

Examiner Signature /Scarlett Goon/	Date Considered 11/08/2011
---	-----------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.